Oragenics, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. The company is a development-stage biotechnology company focused on an intranasal COVID-19 vaccine candidate and lantibiotic antibiotics; it reported only grant revenue and no meaningful commercial product revenue. Comparative 2022 figures below are restated. All share and per-share figures reflect the 1-for-60 reverse stock split effective January 2023.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Grant revenue | $13,163 | $30,391 | $30,187 | $45,474 |
| Research and development expense | $2,006,696 | $2,590,032 | $3,679,272 | $5,883,693 |
| General and administrative expense | $1,115,785 | $1,044,334 | $2,365,048 | $2,375,883 |
| Operating loss | $(3,109,318) | $(3,604,465) | $(6,014,133) | $(8,215,082) |
| Net loss | $(3,050,586) | $(3,589,543) | $(5,895,423) | $(8,180,536) |
| Basic and diluted loss per share | $(1.51) | $(1.85) | $(2.91) | $(4.22) |
For the six months, operating cash use was $4.69 million, down from $9.02 million in the prior-year period. Cash and cash equivalents were $6.47 million at June 30, 2023, compared with $11.43 million at December 31, 2022. Working capital was $6.96 million, versus $12.68 million at year-end. Total assets were $8.46 million and shareholders’ equity was $7.26 million.
No short-term notes payable remained at June 30; operating lease liabilities totaled $255,994, including $190,242 current and $65,752 long-term. No income tax benefit was recorded. Commercial profit or margins are not meaningful because the company has not generated significant operating revenue.
Material changes versus the prior comparable period
- Six-month R&D expense fell 37%, principally reflecting lower COVID vaccine development costs; management said spending was being managed around preclinical work and available capital. Q2 R&D fell 23% year over year.
- Six-month net loss narrowed by $2.29 million, and operating cash use declined by $4.33 million. The company attributed lower cash use primarily to lower losses and changes in operating assets and liabilities.
- Interest income increased, contributing to higher net other income. Grant revenue declined as the related small-business research grant approached expiration.
- Q2 G&A figures show an increase of $71,451 year over year, although the MD&A describes this as a decrease. This is an internal inconsistency in the filing.
Outlook, risks, contingencies, and unusual items
- Going concern and funding: Management said June 30 cash was expected to fund the business as then structured only through Q4 2023 and disclosed substantial doubt about the company’s ability to continue as a going concern beyond that point. Additional financing is necessary; availability and terms are uncertain. Failure to raise funds could force further cuts, delays, or termination of development programs.
- Development outlook: The company anticipated being positioned to file an IND in the United States and/or a Clinical Trial Application in Canada and commence a Phase 1 study of NT-CoV2-1 in the second half of 2023. Further clinical development depends on additional funding, grants, partnerships, or other financing. These are forward-looking plans, not assurances.
- Program prioritization: Cost-saving measures reduced effort and staff focused on lantibiotics, which management said would negatively affect that program. The company also said it was evaluating strategic alternatives for its programs and other assets, potentially including a sale, spin-off, financing, combination, winding down R&D, or liquidation of assets.
- Post-quarter financing and dilution: On August 4, 2023, the company closed a private placement of 404,728 common shares and 404,728 Series E mirroring preferred shares for approximately $850,000 gross proceeds. The filing states proceeds are for general corporate purposes. The company reported 2,539,385 common shares outstanding as of August 10, 2023.
- Other commitments: Inspirevax license milestone obligations range from $0.1 million to $7.25 million, in addition to royalties, if applicable milestones are reached. The May 2023 collaborative project with Inspirevax and the NRC has an estimated budget of approximately C$1.7 million over 27 months, with CQDM expected to fund about 40% of project costs.
- Restatement and controls: The company restated 2022 interim financial statements after upfront vendor payments for R&D were incorrectly expensed rather than recorded as prepaid expenses. Management identified a material weakness in review of R&D contracts and concluded disclosure controls and internal control over financial reporting were not effective; remediation was ongoing, with no assurance of success or timing.
- The company reported no material pending legal proceedings. It cited risks including continued losses, financing shortfalls, clinical and regulatory uncertainty, possible dilution, and potential delays in research or trials.
Important facts for investors to verify
- Whether the August financing and any subsequent funding are sufficient to extend the disclosed Q4 2023 cash runway, and whether additional financing is available on acceptable terms.
- Actual progress and regulatory timing for the NT-CoV2-1 IND/CTA and Phase 1 study, including whether the stated second-half 2023 target was achieved.
- How management is remediating the material weakness and whether any further restatements or control deficiencies arise.
- The Q2 G&A year-over-year direction: the displayed figures indicate an increase, contrary to the MD&A description.
- The terms and potential dilution or rights associated with the Series E mirroring preferred stock, and reconciliation of post-quarter share issuances with reported shares outstanding.